DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
uPSEM817 tartrate (HB8620)
Description:Selective, ultrapotent PSEM agonist for PSAM4-GlyR and PSAM4-5HT3. Brain penetrant.
Purity:>99%
-
Urapidil hydrochloride (HB1693)
Description:Selective 5-HT1A agonist. α1-adrenoceptor antagonist
Purity:>99%
-
Ursodeoxycholic acid (HB4645)
Description:Endogenous hydrophilic bile acid. Antioxidant.
Purity:>95%
-
Valproic acid sodium salt (HB0867)
Description:Histone deacetylase inhibitor. Shows multitude of biological actions. Enables pluripotent stem cell induction from somatic cells.
-
-
Varenicline tartrate (HB2070)
Description:Selective α4β2 nAChR partial agonist; orally active
Purity:>99%
-
-
Venlafaxine hydrochloride (HB1743)
Description:Serotonin/norepinephrine re-uptake inhibitor. Affects differentiation of NSCs.
Purity:>98%
